Repository logo
 
Publication

Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024

2024-06-04Journal article Open access
Simple item page
dc.contributor.authorLaniece Delaunay, Charlotte
dc.contributor.authorMelo, Aryse
dc.contributor.authorMaurel, Marine
dc.contributor.authorMazagatos, Clara
dc.contributor.authorGoerlitz, Luise
dc.contributor.authorO’Donnell, Joan
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorSève, Noémie
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorMeijer, Adam
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorLazăr, Mihaela
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorBennett, Charlene
dc.contributor.authorTúri, Gergő
dc.contributor.authorRameix-Welti, Marie-Anne
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorCastilla, Jesús
dc.contributor.authorHooiveld, Mariëtte
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorSamuelsson Hagey, Tove
dc.contributor.authorDijkstra, Frederika
dc.contributor.authorBorges, Vitor
dc.contributor.authorRamos Marín, Violeta
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorKissling, Esther
dc.contributor.authorEuropean primary care VE group
dc.date.accessioned2025-03-11T14:39:45Z
dc.date.available2025-03-11T14:39:45Z
dc.date.issued2024-06-04
dc.descriptionErratum in: Vaccine. 2024 Oct 3;42(23):126089. https://doi.org/10.1016/j.vaccine.2024.06.056. Epub 2024 Jul 8.
dc.description.abstractIn autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a testnegative case–control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26–53 %) overall, 48 % (95 % CI: 31–61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3–49 %) at 6–14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies.pt_PT
dc.description.sponsorshipThis study has received funding from the European Centre for Disease Prevention and Control under framework contract ECDC/2021/ 019.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationVaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4
dc.identifier.doi10.1016/j.vaccine.2024.05.067pt_PT
dc.identifier.issn0264-410X
dc.identifier.pmid38839521
dc.identifier.urihttp://hdl.handle.net/10400.18/10431
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relationECDC/2021/ 019pt_PT
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S0264410X24006443?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectMulticentre Studypt_PT
dc.subjectTest-Negative Designpt_PT
dc.subjectEurope
dc.subjectInfecções Respiratórias
dc.subjectInvestigação em Serviços de Saúdept_PT
dc.subjectEstados de Saúde e de Doençapt_PT
dc.titleEffectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage3937pt_PT
oaire.citation.issue19pt_PT
oaire.citation.startPage3931pt_PT
oaire.citation.titleVaccine
oaire.citation.volume42pt_PT
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMelo
person.familyNameRodrigues
person.familyNameGuiomar
person.familyNameBorges
person.givenNameAryse Martins
person.givenNameAna Paula
person.givenNameRaquel
person.givenNameVitor
person.identifier.ciencia-id6A11-17A6-1790
person.identifier.ciencia-idAE10-5FAB-7439
person.identifier.orcid0000-0002-6655-8715
person.identifier.orcid0000-0003-2264-4723
person.identifier.orcid0000-0002-4563-6315
person.identifier.orcid0000-0003-1062-0759
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication4e4a43a9-1c7b-4690-a976-98c003a89bf4
relation.isAuthorOfPublicationc23c6d96-e605-424f-abbb-64d783c73939
relation.isAuthorOfPublication9743082d-bed6-4e5e-94f5-1d27bb037bb0
relation.isAuthorOfPublicationc975f890-36a8-4fb1-b182-091cc2ebc63d
relation.isAuthorOfPublication.latestForDiscovery4e4a43a9-1c7b-4690-a976-98c003a89bf4

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S0264410X24006443-main.pdf
Size:
619.54 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais